[go: up one dir, main page]

DE60237044D1 - Immunogene peptidzusammensetzung zur prävention und behandlung der alzheimer-krankheit - Google Patents

Immunogene peptidzusammensetzung zur prävention und behandlung der alzheimer-krankheit

Info

Publication number
DE60237044D1
DE60237044D1 DE60237044T DE60237044T DE60237044D1 DE 60237044 D1 DE60237044 D1 DE 60237044D1 DE 60237044 T DE60237044 T DE 60237044T DE 60237044 T DE60237044 T DE 60237044T DE 60237044 D1 DE60237044 D1 DE 60237044D1
Authority
DE
Germany
Prior art keywords
peptide
prevention
treatment
alzheimer
soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60237044T
Other languages
English (en)
Inventor
Chang Yi Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Biomedical Inc
Original Assignee
United Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Biomedical Inc filed Critical United Biomedical Inc
Application granted granted Critical
Publication of DE60237044D1 publication Critical patent/DE60237044D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60237044T 2001-05-25 2002-04-02 Immunogene peptidzusammensetzung zur prävention und behandlung der alzheimer-krankheit Expired - Lifetime DE60237044D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/865,294 US6906169B2 (en) 2001-05-25 2001-05-25 Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
PCT/US2002/010293 WO2002096350A2 (en) 2001-05-25 2002-04-02 Immunogenic peptide composition for the prevention and treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
DE60237044D1 true DE60237044D1 (de) 2010-08-26

Family

ID=25345158

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60237044T Expired - Lifetime DE60237044D1 (de) 2001-05-25 2002-04-02 Immunogene peptidzusammensetzung zur prävention und behandlung der alzheimer-krankheit
DE60239093T Expired - Lifetime DE60239093D1 (de) 2001-05-25 2002-04-02 Immunogene Peptidzusammensetzung zur Prävention und Behandlung der Alzheimer-Krankheit

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60239093T Expired - Lifetime DE60239093D1 (de) 2001-05-25 2002-04-02 Immunogene Peptidzusammensetzung zur Prävention und Behandlung der Alzheimer-Krankheit

Country Status (15)

Country Link
US (3) US6906169B2 (de)
EP (2) EP1497313B1 (de)
JP (3) JP4440544B2 (de)
CN (2) CN1568329B (de)
AT (2) ATE496937T1 (de)
AU (2) AU2002303211B2 (de)
BR (1) BRPI0210010B8 (de)
CA (2) CA2448171A1 (de)
DE (2) DE60237044D1 (de)
DK (2) DK2123671T3 (de)
ES (2) ES2360465T3 (de)
MX (1) MXPA03010631A (de)
TW (1) TWI252233B (de)
WO (1) WO2002096350A2 (de)
ZA (1) ZA200308767B (de)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20050059591A1 (en) * 1998-04-07 2005-03-17 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
BR0108566A (pt) * 2000-02-21 2002-11-19 Pharmexa As Método para a regulação negativa in vivo de proteìna amilóide em um animal, incluindo um ser humano e para o tratamento e/ou prevenção e/ou melhora da doença de alzheimer ou outras doenças e condições cartacterizadas por depósitos de amilóide, análogo de um polipeptìdeo amiloidogênico,composição imunogênica, fragmento de ácido nucleico, vetor, célula transformada, composição para induzir a produção de anticorpos contra um polipeptìdeo amiloidogênico, linhagem celular estável, métodos para a preparação de uma célula, para a identificação de um polipeptìdeo amiloidogênico modificado, e para preparação de uma composição imunogênica, uso de um polipeptìdeo amiloidogênico ou de uma subsequência do mesmo, e, uso de um análogo de um polipeptìdeo amiloidogênico
AU783144B2 (en) * 2000-02-21 2005-09-29 H. Lundbeck A/S Novel method for down-regulation of amyloid
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
WO2003045128A2 (en) * 2001-11-21 2003-06-05 New York University SYNTHETIC IMMUNOGENIC BUT NON-DEPOSIT-FORMING POLYPEPTIDES AND PEPTIDES HOMOLOGOUS TO AMYLOID β, PRION PROTEIN, AMYLIN, α-SYNUCLEIN, OR POLYGLUTAMINE REPEATS FOR INDUCTION OF AN IMMUNE RESPONSE THERETO
US8088388B2 (en) * 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
US20040001848A1 (en) * 2002-03-01 2004-01-01 Szu-Yi Chou Method of producing disease-specific antigens
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP2330113B1 (de) * 2002-04-19 2016-06-29 The Governing Council Of The University Of Toronto Immunologisches Verfahren und Zusammensetzungen für die Behandlung der Alzheimer Krankheit
AU2003250102B2 (en) * 2002-07-24 2009-09-17 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
JP4888876B2 (ja) 2003-06-13 2012-02-29 田平 武 アルツハイマー病の治療のための組換えアデノ随伴ウィルスベクター
EP1515158B1 (de) * 2003-09-09 2013-07-17 Esaote S.p.A. Ultraschall-Bilderzeugungsverfahren mit Kontrastmittel-Anwesenheit in dem Aufnahmeobjekt
BRPI0417689A8 (pt) 2003-12-17 2017-04-25 Elan Pharm Inc Método para conjugar um imonógeno de peptídeo, composição, conjugado, composição imunogênica, método para induzir uma resposta imune em um indivíduo mamífero, e, uso do conjugado
JP2007522119A (ja) * 2004-01-28 2007-08-09 キュリックス エーピーエス アミロイド関連疾患用ワクチンとしてのアミロイドタンパク質のコンジュゲート
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
GB0427267D0 (en) * 2004-12-13 2005-01-12 Maria Teresa De Magistris Peptide adjuvants
AR051528A1 (es) * 2004-12-15 2007-01-17 Neuralab Ltd Anticuerpos humanizados que reconocen el peptido beta amiloideo
US8916165B2 (en) * 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
AR051800A1 (es) * 2004-12-15 2007-02-07 Wyeth Corp Anticuerpos a beta usados en mejorar la cognicion
AU2006319358B2 (en) 2005-11-30 2012-01-19 AbbVie Deutschland GmbH & Co. KG Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
KR20140087058A (ko) 2005-11-30 2014-07-08 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
NZ568384A (en) * 2005-12-12 2011-09-30 Ac Immune Sa Therapeutic vaccine comprising Abeta peptide
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
KR20080103560A (ko) 2006-02-22 2008-11-27 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 항 아밀로이드-β-펩티드 항체 생산 유도용 펩티드 백신
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
CN101058608B (zh) * 2006-04-21 2011-02-23 杜如昱 人类抗Aβ1-32淀粉样蛋白抗体、其纯化方法及用途
CA2653628C (en) 2006-06-01 2015-07-14 Elan Pharmaceuticals, Inc. Neuroactive fragments of app
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
CN101970000A (zh) * 2007-04-18 2011-02-09 杨森阿尔茨海默氏症免疫治疗公司 脑淀粉样血管病的预防和治疗
WO2008133208A1 (ja) * 2007-04-20 2008-11-06 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute ペプチド免疫応答増強方法
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2106802A1 (de) 2008-04-02 2009-10-07 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Modifizierte Peptide als synthetische Impfungen bei Amyloid-bedingten Krankheiten
CA2739318A1 (en) 2008-08-07 2010-02-11 Mercia Pharma, Llc Immunotherapeutic compositions for the treatment of alzheimer's disease
WO2010080188A2 (en) * 2008-10-14 2010-07-15 The Regents Of The University Of Michigan Epitope targeted anthrax vaccine
EP2348042B1 (de) * 2008-10-16 2017-07-05 The Chemo-Sero-Therapeutic Research Institute Modifiziertes amyloid-beta-peptid
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
DE102008037564A1 (de) 2008-11-19 2010-05-20 Forschungszentrum Jülich GmbH Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden
US8748386B2 (en) 2009-06-10 2014-06-10 New York University Immunological targeting of pathological Tau proteins
US20110221240A1 (en) * 2010-03-11 2011-09-15 Ziming Shen Compact children's table and stool set
CA2796339C (en) 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
MX352641B (es) 2010-07-08 2017-12-01 United Biomedical Inc Vacuna contra pcv2 basada en peptidos de diseño.
JP6147665B2 (ja) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
US20120321694A1 (en) * 2010-10-27 2012-12-20 Daniel Larocque Compositions and uses
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
CN102775478B (zh) * 2012-08-10 2013-06-19 申联生物医药（上海）有限公司 口蹄疫病毒抗原多肽及疫苗
JP2015527369A (ja) * 2012-08-21 2015-09-17 インスティテュート フォー モレキュラー メディシン， インコーポレイテッド アミロイド、タウおよびα−シヌクレインの沈着に関連する疾患に関する組成物および方法
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
WO2015017280A1 (en) 2013-07-28 2015-02-05 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
TWI609026B (zh) * 2014-03-14 2017-12-21 美國聯合生物醫學公司 抑制與免疫治療阿茲海默型癡呆的胜肽疫苗
JP2021508672A (ja) * 2017-06-16 2021-03-11 ユナイテッド ニューロサイエンスＵｎｉｔｅｄ Ｎｅｕｒｏｓｃｉｅｎｃｅ シヌクレイノパチーの治療のためのアルファ−シヌクレインタンパク質のｃ末端からのペプチド免疫原及びその製剤
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
SG11202003624SA (en) * 2017-10-27 2020-05-28 United Neuroscience Tau peptide immunogen constructs
BR112020013352A2 (pt) * 2017-12-31 2020-12-01 United Biomedical, Inc. imunógenos de peptídeo e formulações dos mesmos direcionados a ige ligada a membrana para tratamento de doenças alérgicas mediadas por ige
AU2019262609A1 (en) * 2018-05-04 2020-12-03 Ubi Ip Holdings Artificial promiscuous T helper cell epitopes that facilitate targeted antibody production with limited T cell inflammatory response
EP3861007A4 (de) * 2018-10-01 2022-07-13 United Neuroscience Gegen dipeptid-repeat-proteine aus c9orf72 gerichtete peptid-immunogen-konstrukte
US20230218748A1 (en) * 2018-12-19 2023-07-13 United Biomedical, Inc. Artificial promiscuous t helper cell epitopes as immune stimulators for synthetic peptide immunogens
TWI769424B (zh) * 2018-12-31 2022-07-01 美商Ｕｎｓ Ｉｐ控股公司 針對降鈣素基因相關胜肽（ｃｇｒｐ）的胜肽免疫原及其用於預防和治療偏頭痛的製劑
JP2022523333A (ja) 2019-01-30 2022-04-22 トゥルーバインディング，インコーポレイテッド 抗ｇａｌ３抗体およびその使用
CN110684122B (zh) * 2019-10-29 2021-03-02 中国人民解放军军事科学院军事医学研究院 重组Tau表位嵌合多聚体抗原、其制备方法和应用
EP4153210A4 (de) * 2020-05-19 2024-11-13 Othair Prothena Limited Multiepitop-impfstoff zur behandlung von morbus alzheimer
EP4157338A4 (de) 2020-05-26 2024-11-13 TrueBinding, Inc. Verfahren zur behandlung von entzündungskrankheiten durch galectin-3-blockierung
US20220383996A1 (en) * 2021-05-27 2022-12-01 Amazon Technologies, Inc. Assigning peptides to peptide groups for vaccine development
US12537072B1 (en) 2021-05-27 2026-01-27 Amazon Technologies, Inc. Immunogenic response prediction based on major histocompatibility complex (MHC) data
CN113603773B (zh) * 2021-08-17 2023-05-09 中国医科大学附属第一医院 靶向淀粉样蛋白的单克隆抗体7b8、分泌该抗体的杂交瘤细胞株及应用
EP4395894A4 (de) * 2021-09-01 2025-08-06 Vaxxinity Inc Verfahren zur prävention und behandlung von synukleinopathien
CN117327168A (zh) * 2022-06-24 2024-01-02 厦门大学 B2M-GluN1封闭肽、其药物组合物及用途
CN116063447B (zh) * 2022-09-13 2023-11-03 北京湃德智健科技有限公司 用于检测adap自身抗体的抗原多肽及其应用
CN121001737A (zh) * 2023-01-26 2025-11-21 瓦克西尼提股份有限公司 Tau和β淀粉样肽免疫原组合物及相关方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753624A (en) * 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
ATE153534T1 (de) 1990-04-27 1997-06-15 John Mcmichael Verfahren und zusammensetzung zur behandlung von erkrankungen des zns hervorgerufen durch abnormales beta-amyloid-protein
US5955317A (en) * 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
EP1308461A3 (de) * 1993-01-25 2004-02-11 Takeda Chemical Industries, Ltd. Antikörper gegen Beta-Amyloiden oder deren Abarten, und deren Verwendungen
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
ES2180576T3 (es) * 1993-04-27 2003-02-16 United Biomedical Inc Construcciones peptidicas de lhrh inmunogenicas y estimuladores de inmunidad universales sinteticos para vacunas.
AU7043894A (en) * 1993-05-28 1994-12-20 Miriam Hospital, The Composition and method for (in vivo) imaging of amyloid deposits
EP0725838A4 (de) 1993-10-26 1997-02-26 United Biomedical Inc Strukturierte synthetische antigenbanken als diagnostika, impfstoffe und therapeutische mittel
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
TWI229679B (en) 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
US6025468A (en) * 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
ATE461996T1 (de) * 1999-09-03 2010-04-15 Univ Ramot Verbindungen, zusammensetzungen und verfahren zur behandlung oder vorsorge von alzheimer erkrankung
EP1237930B1 (de) * 1999-12-08 2006-11-08 Intellect Neurosciences, Inc. Schimärische amyloid-beta peptide
US20030165481A1 (en) 2000-02-24 2003-09-04 Hersh Louis B. Amyloid peptide inactivating enzyme to treat Alzheimer's disease
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide

Also Published As

Publication number Publication date
US7951909B2 (en) 2011-05-31
US6906169B2 (en) 2005-06-14
JP2009227683A (ja) 2009-10-08
EP1497313B1 (de) 2010-07-14
CN1568329B (zh) 2013-07-17
US20030068325A1 (en) 2003-04-10
US20110070255A1 (en) 2011-03-24
TWI252233B (en) 2006-04-01
DK1497313T3 (da) 2010-10-25
CN101372511B (zh) 2012-12-26
AU2008202270B2 (en) 2010-06-17
AU2002303211B2 (en) 2008-02-28
BRPI0210010B8 (pt) 2021-05-25
US20040247612A1 (en) 2004-12-09
EP2123671B1 (de) 2011-01-26
MXPA03010631A (es) 2004-09-13
ZA200308767B (en) 2005-09-28
HK1127898A1 (en) 2009-10-09
JP4440544B2 (ja) 2010-03-24
CN1568329A (zh) 2005-01-19
EP1497313A2 (de) 2005-01-19
ATE474000T1 (de) 2010-07-15
WO2002096350A3 (en) 2004-11-11
JP2005506311A (ja) 2005-03-03
DK2123671T3 (da) 2011-05-02
EP1497313A4 (de) 2005-11-16
AU2008202270A1 (en) 2008-06-12
JP5300592B2 (ja) 2013-09-25
ES2360465T3 (es) 2011-06-06
US8232373B2 (en) 2012-07-31
JP5300593B2 (ja) 2013-09-25
CA2665748C (en) 2014-01-21
ATE496937T1 (de) 2011-02-15
BRPI0210010B1 (pt) 2018-03-20
JP2009221213A (ja) 2009-10-01
HK1068215A1 (en) 2005-04-22
BR0210010A (pt) 2005-10-25
CN101372511A (zh) 2009-02-25
ES2348975T3 (es) 2010-12-20
DE60239093D1 (de) 2011-03-10
EP2123671A1 (de) 2009-11-25
CA2665748A1 (en) 2002-12-05
CA2448171A1 (en) 2002-12-05
WO2002096350A2 (en) 2002-12-05

Similar Documents

Publication Publication Date Title
ATE474000T1 (de) Immunogene peptidzusammensetzung zur prävention und behandlung der alzheimer-krankheit
AU2006326283B2 (en) Therapeutic vaccine
IL164643A (en) Peptides, immunogenic compositions containing them and use thereof for the preparation of medicaments for the treatment of alzheimer's disease
NO20022531L (no) Vaksine for forebyggelse og behandling av Alzheimer- og amyloidrelaterte sykdommer
NO20100264L (no) Forhindring og behandling av amyloidogen sykdom
AU2002302255A1 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
ATE535252T1 (de) Peptid-konjugat-zusammensetzungen und -verfahren zur prävention und behandlung von alzheimer- krankheit
BR0212999A (pt) novas composições imunogênicas para a prevenção e tratamento de doença meningocócica
ATE364623T1 (de) Peptid zur diagnose und therapie der alzheimer- demenz
WO2005058940A2 (en) Immunogenic peptide carrier conjugates and methods of producing same
ATE456378T1 (de) Behandlung und verhütung von neoplasmatischen und infektiösen erkrankungen mit hitzeschock / stress proteinen
HUP0303173A2 (hu) Csökkent immunogenitású, módosított anti-EGFR-ellenanyagok
PT1409654E (pt) Controlo imunológico dos níveis de beta-amilóide in vivo
WO2001053457A3 (en) Vaccines against neurodegenerative disorders